CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Barostim Neo Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01484288
NCT01484288N/ACompleted

Baroreflex Activation Therapy in Heart Failure

CVRx, Inc.·interventional·Posted Dec 2, 2011·Updated Aug 26, 2021

In Brief

A clinical study evaluating Barostim Neo System for Heart Failure. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this clinical investigation is to evaluate the efficacy and safety of the CVRx Barostim Neo System in the treatment of patients with heart failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2, 2011
Enrollment StartNov 1, 2011
Primary CompletionJul 1, 2013
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.6 years ago

Interventions

Barostim Neo Systemdevice

Baroreflex Activation Therapy using the Barostim Neo System